相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Bayer has agreed to sell rights to its oral cancer drug Stivarga to Germany's Grünenthal Group for up to 375 million euros, or about 430.7 million dollars. - Stivarga is approved for metastatic colorectal cancer, hepatocellular carcinoma and gastrointestinal stromal tumors, and has treated more than one million patients in over 90 countries. - Grünenthal said the acquisition advances its strategy of buying established drugs that serve continuing medical needs and should add up to about 100 million euros to 2027 EBITDA. - The transaction is expected to close by the end of 2026 or early 2027, with Stivarga losing EU patent protection in 2029 and US protection a year later.
- Bayer reported Q2 2026 net sales of EUR 10.9 billion, up 2% year-over-year, with first-half sales reaching EUR 24.3 billion, up 3%. - Pharma sales were broadly flat, but Nubeqa and Kerendia together grew 66%, offsetting a sharp 27% decline in Eylea driven by biosimilar competition. - The anticoagulant asundexian received priority review in the U.S. and China, with launches targeted around end-2026 or early-2027. - First-half free cash flow was negative EUR 2.7 billion, weighed by roughly EUR 2.5 billion in litigation payouts, while a favorable U.S. Supreme Court ruling strengthened Bayer's litigation containment strategy.
- Apollo-managed funds are acquiring a 37% minority stake in Syntegon, the pharmaceutical and biotech packaging equipment manufacturer, while CVC Capital Partners retains 63% ownership. - Syntegon posted record revenue of €1.75 billion in 2025 with EBITDA rising 27% year-on-year to €282 million, representing a quadrupling of operating profit since CVC's 2019 investment. - The strategic partnership aims to accelerate Syntegon's expansion into North American markets and capitalize on aftermarket services from its 72,000 installed systems worldwide. - The company recently launched SynTiso, described as the world's first gloveless high-speed filling line for liquid pharmaceuticals, targeting sterile manufacturing operations.
